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Telomeres and Cardiovascular Disease
Does Size Matter?
Antonio L. Serrano, Vicente Andrés
Abstract—Telomeres—the specialized DNA-protein structures at the ends of eukaryotic chromosomes—are essential for
maintaining genome stability and integrity and for extended proliferative life span in both cultured cells and in the whole
organism. Telomerase and additional telomere-associated proteins are necessary for preserving telomeric DNA length.
Age-dependent telomere shortening in most somatic cells, including vascular endothelial cells, smooth muscle cells, and
cardiomyocytes, is thought to impair cellular function and viability of the aged organism. Telomere dysfunction is
emerging as an important factor in the pathogenesis of hypertension, atherosclerosis, and heart failure. In this Review,
we discuss present studies on telomeres and telomere-associated proteins in cardiovascular pathobiology and their
implications for therapeutics. (Circ Res. 2004;94:575-584.)
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Telomeres are specialized DNA-protein complexes lo-cated at the ends of linear chromosomes of eukaryotes
that preserve genome integrity and stability by preventing the
recognition of chromosomal ends as double-stranded DNA
breaks. The telomeric complex is composed of noncoding
double-stranded repeats of G-rich tandem DNA sequences
(TTAGGG in humans) that are extended several thousand
base pairs and end in a 3 single-stranded overhang, the
enzyme telomerase, and several associated proteins with
structural and regulatory roles that participate in the control
of telomere length and capping (ie, TRF1, TRF2, and Ku86)
(Figures 1A and 1B). Telomerase has two components, a
catalytic telomerase reverse transcriptase (TERT) and a
telomerase RNA component (Terc) that serves as a template
for the synthesis of new telomeric DNA repeats (Figure 1B).
The telomeric structure and the complex regulation of telo-
mere dynamics is thoroughly discussed elsewhere.1,2
Most adult somatic cells exhibit low or absent telomerase
activity and thus experience progressive telomere attrition
with each mitotic cycle, both in cell culture as a function of
population doublings and during aging of the whole organ-
ism3–5 (Figure 1C). In contrast, germ and tumor cells maintain
high telomerase activity and long telomeres and thus have an
extended proliferative potential. Notably, forced overexpres-
sion of TERT inhibits replicative senescence and extends life
span in numerous cell types. The Table summarizes studies
on telomeres and telomerase in the biology of cultured
cardiomyocytes, smooth muscle cells (SMCs), and endothe-
lial cells (ECs). Notably, telomere shortening is accelerated in
human premature aging syndromes (ie, Werner syndrome,
ataxia telangiectasia, and dyskeratosis congenita).
The validity of telomere length by itself as an indicator of
cell viability or aging has been challenged by the present
model of the telomere complex, which postulates a dynamic
switch between a protected or capped state and a temporarily
uncapped state.6 Telomere homeostasis is regulated through
mutually reinforcing mechanisms, such as its precise protein
composition, telomere length, and telomerase activity level.
The probability of telomere uncapping increases when one or
more of these parameters are critically altered and cannot be
compensated by the others. For instance, telomerase is
dispensable in cells with sufficiently long telomeres, but cells
with critically short telomeres that lack telomerase lose their
ability to proliferate (replicative senescence). Telomere dys-
function can provoke chromosomal fusions and apoptotic cell
death.
Telomerase expression and activity and telomere length are
tissue-regulated and developmentally regulated, with gener-
ally greater telomerase activity during embryonic develop-
ment and low or undetectable levels soon after birth. For
instance, telomerase activity in rat embryos is highest in liver
and lowest in brain and becomes undetectable in all adult
organs examined but in liver,7 and telomere length decreases
with aging in rat kidney, liver, pancreas, and lung but not in
brain.8 In mice, similar telomere length was found in liver,
brain, testis, kidney, and spleen of newborns, but this param-
eter differed among tissues in adults.9 Significant age-
dependent telomere shortening in Mus spretus was found in
spleen and brain but not in liver, testis, or kidney, and
telomerase activity was abundant in adult liver and testis but
weak to undetectable in spleen, kidney, and brain.10 Although
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human telomere reduction rates of 29 to 60 bp per year have
been estimated in the liver, renal cortex, and spleen, telomere
length is maintained in cerebral cortex.11
Individual differences in telomere length in rodents9,10 and
humans11–15 suggest that this parameter is genetically deter-
mined. Moreover, human and animal studies revealed higher
telomerase activity16 and longer telomeres8,10,17 in females
versus males, and estrogens may contribute to these gender
differences (see below). It is also noteworthy that human
TERT (hTERT) is alternatively spliced in specific patterns in
different tissue types during human development, and this
mechanism often leads to the expression of hTERT protein
lacking functional reverse-transcriptase domains.18
The impact of telomere ablation in the whole organism has
been rigorously assessed in Terc-deficient mice.19–26 Notably,
the breeding of successive generations of Terc-null mice is
necessary to reach critical telomere ablation, leading to
increased chromosome end-to-end fusions and alterations
characteristic of premature aging and disease, such as infer-
tility, graying of hair, alopecia, impaired wound healing,
Figure 1. Telomeres, telomerase, and
cellular proliferation. A, left, Telomeres
(yellow) at both ends of chromosomes
(blue) revealed by Q-FISH. Right,
Scheme showing the sequence of the
tandem repeat present in human telo-
meric DNA. B, Protein composition of
the human telomerase ribonucleoprotein
complex has been only partly character-
ized. The scheme shows the DNA and
RNA (Terc) telomeric components, the
catalytic telomerase reverse transcrip-
tase (TERT) subunit, and additional
telomerase-associated proteins. C,
Telomerase activity is low or absent in
most somatic cells; therefore, progres-
sive telomere erosion occurs in these
cells with each mitotic cycle during nor-
mal aging or passage in culture. Germ
and tumor cells display high telomerase
activity, thus ensuring the maintenance
of telomere length and an extended pro-
liferative potential. Accelerated telomere
attrition is associated with human pre-
mature aging syndromes.
In Vitro Studies Implicating Telomeres and Telomerase in Cardiovascular Cell Function
Cell Type Main Findings References
Cardiac myocyte Overexpression of hTERT induces hypertrophy and inhibits apoptosis in culture 68
TRF2 inactivation causes telomere erosion, Chk2 activation, and increases apoptosis in cultured rat
ventricular myocytes
71
Smooth muscle cell (SMC) Hypoxia-induced human SMC growth correlates with telomerase activation 28
Telomerase activity in primary SMCs correlates with cell proliferation, and telomerase inhibition
diminishes cell growth
62, 95
Forced expression of hTERT extends life span of rat SMCs 87
Endothelial cell (EC) Limited proliferative capacity of passaged human ECs correlates with telomere attrition 52
Inhibition or forced expression of telomerase in human aortic ECs affects cell life span 54, 96
Constitutive hTERT expression enhances the regenerative capacity of endothelial progenitor cells 33
Estrogen activates the PI3K/Akt pathway in human ECs, and both PI3K inhibition and dominant-negative Akt
mutant significantly reduce telomerase activity in EC cultures; in contrast, Akt activation enhances
human telomerase activity
39, 40, 41
Oxidized low-density lipoproteins inactivate Akt and diminish telomerase activity in ECs 41
Estrogen stimulates nitric oxide production in vascular ECs, which in turn induces telomerase in these cells 39, 42
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small intestine and spleen atrophy, reduced proliferation of T
and B lymphocytes, and hematopoietic disorders. These
alterations, which are most prominent in highly proliferative
organs, are associated with a significant reduction in life
span. Studies using this animal model that are relevant for
cardiovascular pathobiology will be discussed in the next
sections.
Telomeres and Neovascularization
The restoration of blood flow into ischemic territories in the
adult organism depends on the development of new collateral
vessels from established vascular networks (angiogenesis)
and on de novo vessel formation by endothelial progenitor
cells (vasculogenesis).27 New capillaries composed by a
monolayer of ECs are stabilized and mature into fully
functional vessels on the recruitment of SMCs and pericytes.
Hypoxia is a fundamental angiogenic stimulus that induces
TERT protein expression and phosphorylation in cultured
SMCs.28 Telomerase inhibition shortened the life span of
hypoxic cultures, and constitutive TERT expression extended
life span under normoxia, suggesting that hypoxia-mediated
telomerase activation promotes long-term SMC growth.
Whether chronic hypoxia also leads to higher telomerase
activity in ECs remains to be established.
Aging leads to endothelial dysfunction, reduced vascular
endothelial growth factor expression, and diminished angio-
genesis in a rabbit model of limb ischemia, although ad-
vanced age does not preclude augmentation of collateral
vessel development in response to the supply of exogenous
angiogenic factors.29 Late-generation Terc-null mice with
short telomeres disclosed a sharp decrease in angiogenesis in
both Matrigel implants and murine melanoma grafts, and this
correlated with diminished tumor cell proliferation, increased
tumor cell apoptosis, and a lower tumor growth rate.23
Collectively, these studies suggest that telomere ablation
likely impairs angiogenesis in the aged organism.
Pallini et al30 found a direct correlation between hTERT
mRNA expression in ECs of newly formed vessels and the
histological grade of human tumors, thus additionally sup-
porting a role of telomerase in angiogenesis. They detected
endothelial hTERT expression in 29%, 56%, and 100% of
low-grade astrocytomas, anaplastic astrocytomas, and ad-
vanced glioblastomas multiforme, respectively. Whereas
hTERT mRNA expression and the proliferation rate of
human ECs are dissociated in low-grade and anaplastic
astrocytomas, these parameters correlated in glioblastomas
multiforme. Remarkably, diffusible factors produced by
glioblastoma cells in vitro upregulate hTERT mRNA and
protein expression and telomerase activity in ECs.31
Human dermal microvascular ECs transduced with hTERT
have increased capacity to form more durable microvascular
structures when subcutaneously xenografted in severe com-
bined immunodeficiency mice.32 Likewise, constitutive
hTERT expression in cultured human endothelial progenitor
cells enhances their mitogenic and migratory activity, im-
proves survival, and augments neovascularization in a murine
hind limb ischemia model.33
Telomeres and Cardiovascular Disease
The cardioprotective effects of estrogens via indirect actions
on lipoprotein metabolism and through direct effects on
vascular ECs and SMCs are likely to contribute to the lower
incidence of cardiovascular disease observed in premeno-
pausal women compared with men.34–37 Of note in this
regard, women have a decelerated rate of age-dependent
telomere exhaustion over men.8,10,15,17 Estrogen induces
TERT transcription via an estrogen response element within
the TERT promoter.38 Moreover, estrogen activates in human
ECs the phosphoinositol 3-kinase (PI3K)/Akt pathway,39
which in turn enhances human telomerase activity through
TERT phosphorylation.40 In contrast, PI3K inhibition or
dominant-negative Akt diminishes telomerase activity in
ECs.41 Collectively, these findings suggest that estrogen
activates endothelial telomerase via PI3K/Akt signaling. Con-
versely, Akt inactivation by proatherogenic oxidized low
density lipoproteins diminishes telomerase activity in ECs.41
Estrogen also stimulates nitric oxide production in vascular
ECs,39 which in turn induces telomerase in these cells.42
Atherothrombosis is frequently the cause of myocardial
infarction (MI) and consecutive heart failure. Atheroma
development is a complex multifactorial process that involves
distinct cell types and molecular events, including both
adaptive and innate immune mechanisms.43–48 Endothelial
dysfunction in response to atherogenic stimuli (ie, elevated
plasma cholesterol level, hypertension, and diabetes) is ac-
cepted as one of the earliest manifestations of atherosclerosis
at sites of predisposition to atheroma formation. The damaged
endothelium promotes the adhesion and transendothelial mi-
gration of circulating leukocytes. Early fatty streaks contain
mostly highly proliferative macrophages that avidly uptake
lipoproteins to become lipid-laden foam cells. Activated
intimal leukocytes produce a plethora of inflammatory medi-
ators that promote SMC proliferation and migration, thus
additionally contributing to atheroma growth.43,44,49,50 Plaque
rupture or erosion at advanced disease stages can lead to
thrombus formation, resulting in MI or stroke. In the next
sections, we will discuss studies on telomeres and telomere-
associated proteins in cardiovascular pathobiology, including
alterations in telomere homeostasis induced by atherogenic
stimuli, cardiovascular aging, and heart failure, as well as the
cardiovascular phenotype of mice with altered telomerase
function (Figure 2).
Telomeres and Atherosclerosis
Aging is a major cardiovascular risk factor.43,44 ECs from
human abdominal aorta display age-dependent telomere
shortening and increased frequency of aneuploidy.51 A
greater rate of telomere attrition has been estimated in human
ECs from iliac arteries compared with iliac veins (102 versus
47 bp per year, respectively), and age-dependent intimal
telomere loss is greater in the iliac artery versus the internal
thoracic artery (147 versus 87 bp per year, respectively),52 a
vessel subjected to less hemodynamic stress. Similarly,
Okuda et al53 reported a higher rate of age-dependent telo-
mere attrition in both the intima and media of the distal versus
proximal human abdominal aorta. They also found a negative
correlation between telomere length and atherosclerotic
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grade, although this relationship was not statistically signifi-
cant after adjustment for age. Collectively, these studies
suggest that telomere attrition contributes to age-dependent
endothelial dysfunction and reveal a higher rate of telomere
attrition in aged vascular beds with increased shear wall stress
and enhanced cellular turnover.
ECs with senescence-associated phenotypes are present in
human atherosclerotic lesions.54 This phenotype can be in-
duced in cultured human aortic ECs by overexpression of a
dominant-negative mutant of telomere repeat binding factor 2
(TRF2), and replicative senescence of these cells can be
prevented by TERT transduction.54 Interestingly, age-
dependent telomere shortening of cultured human umbilical
vein ECs is slowed down by enrichment of intracellular
vitamin C, which reduces by 53% the level of proatherogenic
reactive oxygen intermediates.55
Leukocytes play important roles in all phases of atheroma
development.43,44,47,48 Patients with vascular dementia, a dis-
order that is frequently associated with progressive cerebro-
vascular atherosclerosis and consecutive stroke, have signif-
icantly shorter telomeres in blood circulating leukocytes
compared with three age-matched control groups, namely
cognitively competent patients suffering from cerebrovascu-
lar or cardiovascular disease alone, patients with probable
Alzheimer’s dementia, and apparently healthy control sub-
jects.56 Likewise, average telomere length in leukocytes of 10
patients with severe coronary artery disease (CAD) was
significantly shorter than that of 20 controls with normal
coronary angiograms after adjustment for age and sex.57 In a
larger study comparing 203 cases of premature MI and 180
controls, age- and sex-adjusted mean terminal restriction
fragment (TRF) length of patients was significantly shorter
than that of controls, and this difference was not accounted
for by other coronary risk factors.58 Compared with subjects
in the highest quartile for telomere length, subjects with
shorter than average telomeres had between 2.8- and 3.2-fold
higher risk of MI. In another study of 143 healthy unrelated
individuals older than 60 years of age, shorter telomere length
in blood DNA correlated with poorer survival that was
attributable in part to a 3.18- and a 8.54-fold higher mortality
rate from heart and infectious disease, respectively.59
The above studies raise the possibility that telomere attri-
tion may be a primary abnormality that renders the organism
more susceptible to cardiovascular risk factors. However,
because the rate of telomere shortening augments in most
somatic cells with increasing cell division,1–5 reduced leuko-
Figure 2. Telomeres and telomerase in cardiovascular disease. A, Association between cardiovascular disease and telomere biology in
different tissues. B, Genetically modified mice as model systems to investigate the role of telomere length and telomerase activity in
cardiovascular pathobiology. Successive generations of Terc-null mice are necessary to reach critically short telomeres and associated
diseases. Reference numbers are shown.
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cyte telomere length in patients with cardiovascular and
cerebrovascular diseases may be a mere consequence of
increased cell turnover induced by the chronic inflammatory
response underlying atherogenesis. To add insight into this
question, we assessed the impact of telomere attrition on
atherogenesis induced by dietary cholesterol in apolipopro-
tein E (apoE)-deficient mice, a well-established model of
experimental atherosclerosis that recapitulates important as-
pects of the human disease.60 We found that late-generation
mice doubly deficient in apoE and Terc had shorter telomeres
and were protected from atherosclerosis compared with
apoE-null mice with an intact Terc gene, and this beneficial
effect of short telomeres correlated with impaired prolifera-
tive capacity of lymphocytes and macrophages.26 Additional
studies are warranted to ascertain whether telomere shorten-
ing affects other key processes implicated in atherosclerosis
(ie, leukocyte recruitment, SMC proliferation, and migra-
tion). If our findings in Terc-apoE doubly deficient mice are
applicable to humans, telomere shortening in blood circulat-
ing leukocytes is unlikely to represent a factor predisposing to
atherosclerosis in humans. However, a conclusive answer to
this chief question must await the results of epidemiological
studies to ascertain if individuals with significantly shorter
telomeres in circulating leukocytes at birth are at higher risk
of developing CAD in adulthood independently of known
cardiovascular risk factors. Of note in this regard, Okuda et
al12 reported high variability of telomeric DNA length in
white blood cells (WBCs), umbilical artery, and skin from
donor newborns independently of gender, suggesting that
genetic and environmental determinants that start exerting
their effect during embryonic development are key determi-
nants of telomere length. These authors also suggested that
longer telomeres in adult women result from a slower rate of
telomeric attrition during aging. X-linked inheritance of
telomere length has recently been suggested.97
Because human aging is associated with telomere erosion
in most somatic cells,4,5 the higher prevalence of atheroscle-
rosis within the elderly seems to challenge the conclusion
made in mice that short telomeres protect from atherosclero-
sis.26 These seemingly conflicting findings might be recon-
ciled if accepting that accumulation of cellular damage
imposed by prolonged exposure to cardiovascular risk factors
ultimately prevails over protective mechanisms, including
telomere shortening. Remarkably, we have shown that 4- to
5-year-old rabbits exhibit a marked reduction in the size of
atherosclerotic lesions compared with 4- to 5-months-old
counterparts despite comparable hypercholesterolemia in-
duced by the same dietary regimen.61
Telomeres, Hypertension, and Diabetes
Hypertension is a major cardiovascular risk factor.46 In
spontaneously hypertensive rats (SHR), both telomerase pro-
tein expression and activity are induced in the aorta but not in
other tissues before the onset of hypertension, and this
correlates with telomere lengthening and increased medial
SMC proliferation.62 TERT antisense RNA delivery in-
creased apoptosis in cultured SMCs by a mechanism that was
reversed by p53 overexpression. The authors concluded that
selective TERT activation and subsequent telomere length-
ening in aortic medial SMCs is the driving force for the
imbalance between cell proliferation and apoptosis that ulti-
mately results in the vascular remodeling seen in genetic
hypertension. Compared with age-matched normotensive
rats, the kidney of SHR undergoes a transient hyperplasic
response during the first 2 weeks of postnatal life.63 Because
shorter telomeres are detected in the kidney of SHR at all ages
examined, it was suggested that kidney cells from these
animals are subjected to increased turnover, potentially lead-
ing to their accelerated aging.
In a study performed on 49 twin pairs that included 38 men
and 60 women 18 to 44 years of age, TRF length in WBCs
correlated positively with diastolic blood pressure but nega-
tively with systolic blood pressure, suggesting a negative
relation between TRF length and pulse pressure.15 Moreover,
the correlation between telomere length and pulse pressure
was independent of gender, and both parameters appeared
highly heritable. Benetos et al17 also investigated WBC
telomere length and blood pressure parameters that are
associated with stiffness of large arteries (pulse pressure and
pulse wave velocity) in French subjects who were not taking
any antihypertensive medications (120 men and 73 women;
mean age, 5611 years). Although telomere length nega-
tively correlated with age in both sexes, multivariate analysis
showed that telomere shortening significantly contributed to
increased pulse pressure and pulse wave velocity only in men.
Both studies found age-adjusted longer telomeres in women,
suggesting that biological aging is more advanced in men
than in women.
Patients with diabetes mellitus are at higher risk for
microvascular and macrovascular disease.45 Jeanclos et al64
reported reduced telomere length in WBCs from patients with
insulin-dependent diabetes mellitus compared with age-
matched nondiabetic subjects. Because this parameter was
undistinguishable when comparing patients with non–insulin-
dependent diabetes mellitus and nondiabetic controls, the
authors suggested that telomere shortening occurs in subsets
of WBCs that play a role in the pathogenesis of insulin-
dependent diabetes mellitus. The observation that CAD
patients with hypercholesterolemia and diabetes mellitus
have shorter telomeres in peripheral blood mononuclear cells
than healthy controls provides additional support implicating
telomere exhaustion as a mechanism contributing to coronary
atherosclerosis under some circumstances of metabolic
disorders.65
Telomeres and Heart Pathobiology
Similar telomere length in the human heart was found in
autopsy samples from 168 individuals in the age range of 0 to
104 years.11 Examination of crude heart extracts revealed a
maximum of telomerase activity in embryos, which then
declines to become very low or undetectable shortly after
birth and throughout adulthood in rodents7,66–68 and hu-
mans.69–71 Telomerase downregulation in the adult heart has
been eluded in transgenic mice engineered to express hTERT
specifically in cardiac myocytes, and this was sufficient to
prevent telomere attrition in adult myocardium.68 Although
the ventricle of 2-week-old transgenic mice displayed in-
creased DNA synthesis and myocyte density, the ratio of
Serrano and Andrés Telomere Dysfunction and Cardiovascular Disease 579
 by on June 16, 2011 circres.ahajournals.orgDownloaded from 
heart weight to body weight did not increase because trans-
genic cardiomyocytes at this age were smaller than wild-type
controls. By 12 weeks, however, there was a concentric
hypertrophy of both ventricles and increased myocyte size,
without evidence of cell loss or alteration of mechanical heart
dysfunction as an explanation. It is noteworthy that this
biphasic response occurred despite sustained telomerase ac-
tivity throughout the period of time examined, suggesting that
hTERT initially delays cardiac myocyte cell-cycle exit and
then induces late-onset cell hypertrophy in mice. In contrast,
hTERT overexpression in primary cultures of postmitotic rat
ventricular myocytes did not elicit DNA synthesis but trig-
gered hypertrophic growth.68
Leri and colleagues16,72 confirmed the postnatal downregu-
lation of cardiac telomerase activity by analyzing highly pure
preparations of rat and dog ventricular myocytes obtained by
enzymatic dissociation. Notably, these authors detected te-
lomerase activity in a restricted population of cardiomyocytes
throughout adulthood and argued that contamination from
fibroblast, EC, and SMC nuclei lacking telomerase is the
most likely cause of the reported lack of telomerase activity
in the whole myocardium from 20-day-old rats.7 Telomerase
expression in adult somatic cells has been also reported in
cycling primary presenescent human fibroblasts,73 previously
believed to lack telomerase activity and expression. Analysis
of telomere length in myocyte nuclei isolated from the left
ventricle of fetal, neonatal, and adult rats (up to 27 months of
age) additionally supports the notion of cellular heterogeneity
within the adult heart.74 Although this parameter was pre-
served during aging in most cells, telomere shortening in-
creased with age in a subgroup of myocytes that constituted
16% of the entire cell population in aged hearts. Because
telomere attrition is generally more prominent in proliferating
cells, these findings have been interpreted as an indication
that replicative-competent cardiac myocytes exist throughout
life and that these cells may counteract the continuous death
of cells in the aging mammalian rat heart.16,74 Indeed,
contrary to the generally held concept that adult cardiomyo-
cytes irreversibly exit the cell cycle, several studies reported
the presence of proliferating ventricular myocytes in the
normal and pathologic adult mammalian heart of several
species, including humans.75–79
Recent studies have explored the putative role of telomeres
and telomerase in heart pathology. As discussed above,
reduced telomere length in circulating leukocytes has been
associated with increased risk of MI and heart disease and
higher mortality rate.58,59 In an experimental model of pro-
gressive deterioration of cardiac performance and dilated
cardiomyopathy in young dogs, telomerase activity and
protein level in left ventricle myocytes, but not in ECs,
SMCs, and fibroblasts, increased 3 weeks after the onset of
the disease and then were reduced 1 week later.72 Notably, the
percentage of telomerase-competent cardiomyocytes coex-
pressing the proliferation marker Ki67 increased during
disease progression, and their level of telomerase activity
seemed sufficient to preserve telomere length in this model of
acute cardiac failure. In contrast, age-related cardiomyopathy
in humans (characterized by an increase of cell senescence
markers, moderate hypertrophy, and cardiac dilatation) cor-
related with enhanced apoptosis and telomere shortening
despite a 14-fold increase in the number of telomerase-
competent myocytes and twice as much telomerase activity
with respect to age-matched hearts.80 Likewise, heart tissue
from patients affected by cardiac hypertrophy consecutive to
aortic stenosis with a mean duration of 3 years exhibited
increased telomerase activity and a 90- to 120-fold increase in
the number of telomerase-positive cells but a 2.7-fold de-
crease in telomere length.81 Thus, unlike acute dilated car-
diomyopathy in young dogs,72 these human studies demon-
strate telomerase shortening during age-related heart disease
and cardiac hypertrophy despite enhanced telomerase activ-
ity. Oh et al71 also reported age-dependent telomere attrition
in patients with end-stage heart failure at the time of cardiac
transplantation, although they did not detect telomerase
activity in the diseased heart.
In addition to cardiac telomere shortening,71,81 patients
with heart failure disclose induction of the DNA damage-ac-
tivated checkpoint kinase Chk2, downregulation of TRF2
expression, and increased frequency of myocyte apoptosis
compared with control hearts.71 TRF2 downregulation was
not seen in patients with hypertrophic obstructive cardiomy-
opathy, a disease that does not affect ventricular function.
Biomechanical stress induced by 1 week of partial aortic
constriction in mice reproduced the findings made in patients
with heart failure, including telomere shortening, TRF2
downregulation, Chk2 activation, and increased apoptosis in
myocardial tissue.71 Importantly, cardiac-specific hTERT
expression in transgenic mice resulted in maintenance of
TRF2 protein expression, blockade of Chk2 activity, and
diminished cardiac apoptosis after ischemic (coronary liga-
tion) and biomechanical (partial occlusion of the thoracic
aorta) injury, and these effects correlated with reduced area of
MI and less fibrosis and preservation of systolic function,
respectively.68,71 Moreover, TRF2 inhibition caused telomere
erosion, Chk2 activation, and increased apoptosis in cultured
rat ventricular myocytes, and TERT and TRF2 overexpres-
sion reduced the apoptotic rate and increased oxidative stress
induced by serum withdrawal in these cells.71 Collectively,
these studies strongly suggest that TRF2 downregulation and
Chk2 activation contribute to increased cardiomyocyte apo-
ptosis in both human and murine cardiac failure.
The examination of successive generations of Terc-null
mice additionally supports the importance of telomere attri-
tion in cardiac pathology.24 Telomere length in isolated
cardiac myocytes was progressively reduced up to the fifth
generation of Terc-null mice (G5Terc-null). Moreover, old
G5Terc-null mice exhibited shorter telomeres in cardiomyo-
cytes than did younger counterparts, and this led to ventric-
ular dilation, thinning of the myocardium, cardiac dysfunc-
tion, and sudden death. Compared with wild-type mice, heart
sections from G5Terc-null mice revealed increased level of
expression of the tumor suppressor protein p53, reduced
proliferation and increased apoptosis, and a 50% reduction in
the number of left ventricular myocytes. Moreover, a strong
correlation between p53 protein expression and telomere
shortening was found in cardiomyocytes of G5Terc-null
mice. It remains to be established whether systemic alter-
ations in response to telomere attrition in other organs may
580 Circulation Research March 19, 2004
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have contributed to cardiac hypertrophy and heart failure in
this experimental model.
Potential Therapeutic Applications of Telomerase
Gene Transfer for Cardiovascular Disease
As discussed in the previous sections, telomerase attrition is
likely to play an important role in cardiovascular disease.
Thus, telomerase-based gene therapy could be of value for the
treatment of these disorders. Importantly, Samper et al82
demonstrated that critically short telomeres can become fully
functional by restoration of telomerase. They mated heterozy-
gous Terc/ mice to late-generation Terc-null mice, which
have short telomeres, unstable chromosomes, and signs of
premature aging. Analysis of the progeny revealed chromo-
somes with detectable telomeres, absence of chromosomal
instability, and no signs of premature aging in the telomerase-
reconstituted mice.
The exogenous supply of angiogenic cytokines promotes
therapeutic neovascularization in animal models of peripheral
and myocardial ischemia and has shown promising clinical
results.83,84 Ex vivo expanded human endothelial progenitor
cells can also serve as a “supply-side” strategy for therapeutic
neovascularization in experimental animals,85 and in vivo
transplantation of hTERT-transduced endothelial progenitors
improved capillary density and limb salvage in a murine hind
limb ischemia model.33 It is noteworthy, however, that
telomere-independent barriers may limit the transplantation
capacity of hematopoietic stem cells. Indeed, although TERT
overexpression in murine hematopoietic stem cells prevented
telomere attrition in these cells during serial transplantation,
this strategy did not extend their transplantation capacity.86
hTERT overexpression in human aortic SMCs increased
telomere length and extended life span compared with control
cells.87 Late-passage hTERT-transduced SMCs retained a
normal morphology and a differentiated, nonmalignant phe-
notype, and engineered vessels containing human umbilical
vein ECs and hTERT-SMCs disclosed markedly improved
cellular viability and were architecturally and mechanically
superior to vessels generated from control SMCs. Thus, the
production of tissue-engineered human arteries for bypass
surgery may be facilitated by TERT transduction.
Proof of principle for the notion that telomerase reconsti-
tution may prevent or rescue heart disease was provided by
the observation that cardiac-restricted expression of TERT in
transgenic mice protects from age-dependent myocardial
telomere shortening and apoptosis and alleviates the conse-
quences of ischemic and biomechanical injury (ie, reduced
MI area, less fibrosis, and preservation of systolic func-
tion).68,71 Isolation and ex vivo expansion of telomerase-
competent replicating cardiomyocytes found in adult
heart16,72,74 could also support myocardial regeneration.
Moreover, recent studies have reported the isolation of
murine and rat adult heart–derived cardiac progenitor cells
that are capable of homing to injured myocardium when
injected either intravenously88 or directly into the ischemic
heart.89 Grafted cardiac stem cells undergo cardiac differen-
tiation with and without fusion to host cells and can encom-
pass as much as 70% of the injured ventricle. Current issues
regarding the potential use of stem cell transplantation for the
treatment of ischemic heart disease have been comprehen-
sively discussed elsewhere.90,91
Despite encouraging results of gene therapy in preclinical
and clinical studies, major efforts are still required to override
the current practical barriers and limitations placed on most
clinical trials before gene therapy strategies exhibit wide
application, including the development of safer gene delivery
vectors, improvement of transgene expression, and develop-
ment of efficient systems for conditional expression. Aside
from these general considerations, it is worth considering
some issues specifically related to gene therapy for telomere-
length restoration. First, the protection against heart injury
observed in cardiac-specific TERT transgenic mice was
achieved in animals that expressed the transgene throughout
development,68,71 but telomerase gene transfer would most
likely be administered in adult patients whose heart contains
a large fraction of nondividing cardiomyocytes. Of note in
this regard, cardiac-specific TERT transgenic mice displayed
cardiac hyperplasic growth by 2 weeks of age and concentric
hypertrophy of both ventricles and increased myocyte size at
12 weeks of age.68 Additional animal studies are thus war-
ranted to assess whether telomerase reconstitution after injury
is of therapeutic value. A second aspect is the potential of
unwanted effects brought about by telomerase gene transfer
that should be considered in the risk-benefit analysis of this
approach. For instance, indiscriminate proliferation of te-
lomerized cells within the heart may promote cardiac fibrosis
and cancer.92,93 Moreover, because neovascularization is
enhanced by TERT overexpression32,33 and proliferation of
vasa vasorum promotes atherosclerosis,94 grafting of telomer-
ized cells into coronary vessels may worsen atherogenesis in
patients with CAD. This potential risk, as well as additional
unwanted effects attributable to the homing of grafted te-
lomerized cells in sites other than the heart, may be prevented
by the use of cardiac-restricted promoters to drive TERT
expression.
Concluding Remarks
Telomere dysfunction is emerging as an important factor in
the pathogenesis of age-related cardiovascular disease. Crit-
ically short telomeres, an imbalance in the relative level of
telomere-associated proteins, low telomerase activity, or a
combination of these factors can lead to cellular senescence
or apoptosis. Both genetic and environmental factors seem to
control human telomere length, which shows a high degree of
individual variability. It is also notable that estrogens may
contribute to longer telomeres in women compared with
age-matched men, and this correlates with lower incidence of
cardiovascular disease in premenopausal women.
Although a consistent finding in humans is the correlation
between short telomeres in blood circulating leukocytes and
hypertension, diabetes mellitus, CAD, and MI, whether telo-
mere exhaustion is cause or consequence of these pathologies
remains to be established. On the other hand, assessing
whether telomere erosion is an independent cardiovascular
risk factor will require prospective epidemiological studies.
Another important issue is to what extent the observations
made in genetically modified mice affecting telomeric com-
ponents are valid in humans. For instance, although shorter
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telomeres have been detected in human arterial tissue from
atherosclerosis-prone vascular beds and in blood circulating
leukocytes from patients with CAD, telomere shortening in
hypercholesterolemic mice significantly reduced atheroscle-
rosis. Furthermore, although cardiac-specific TERT trans-
genic mice give proof of principle for telomerase reconstitu-
tion as a valid therapy for myocardial regeneration, additional
studies are required to ascertain whether this strategy may be
applicable to humans.
In conclusion, although the role of telomere dysfunction in
cardiovascular disease appears evident, more research is
needed before telomerization can be translated effectively
into clinical practice. Because most reports have focused on
telomerase, future studies aimed at assessing the role of
additional telomere-associated proteins in cardiovascular
pathobiology and their potential implications for therapeutics
are warranted.
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